Vedolizumab recommended for ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has issued final guidance that recommends vedolizumab (Entyvio; Takeda) as an option to treat moderate to severely active ulcerative colitis. Vedolizumab is recommended on the basis that it will be provided to the NHS at a reduced price.
- This noticeboard item was updated on 12 June 2015 to correct the name of vedolizumab
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068712